New hope for stomach cancer patients who have run out of options?
NCT ID NCT07103668
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 22 times
Summary
This study tests a new drug called IMC002 in adults with advanced stomach cancer that has a specific marker (CLDN18.2) and has not responded to at least two prior treatments. About 150 participants will receive either IMC002 or a standard treatment chosen by their doctor. The goal is to see if IMC002 can shrink tumors or delay cancer growth better than current options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese PLA General Hospital, Beijing
RECRUITINGBeijing, 100853, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.